Bausch + Lomb has secured the rights to commercialize a ranibizumab biosimilar in the United States and Canada.
Eye health business Bausch + Lomb said it has entered into an agreement to commercialize in the United States and Canada a ranibizumab biosimilar candidate (Xlucane) currently under development.
The deal is with STADA Arzneimittel AG, of Bad Vilbel, Germany, and its development partner Xbrane, of Solna, Sweden. Xbrane announced last month that it hopes to complete clinical trial enrollment for the age-related macular degeneration agent despite the limitations imposed by coronavirus disease 2019 (COVID-19) issues. Bausch + Lomb is headquartered in Laval, Canada.
The biosimilar references Lucentis, Novartis’ blockbuster drug, which loses its patent exclusivity in the United States this year and in Europe in 2022.
Seeking All Indications
The partners in the biosimilar deal aim to obtain all currently approved indications for Lucentis. In the United States, the agent is approved for wet age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.
STADA and Xbrane will be jointly responsible for finalizing development of the biosimilar, and Xbrane will be the commercial supplier. Bausch + Lomb will handle the sales, marketing, and other commercialization efforts in both the United States and Canada, assuming regulatory approval is obtained.
“We believe that, once approved, this biosimilar ranibizumab candidate will be an excellent addition to our comprehensive eye health portfolio and further deliver on our commitment of continuing to expand and improve upon our ophthalmic portfolio for our customers and their patients,” said Yolande Barnard, vice president and general manage of US Pharmaceuticals for Bausch + Lomb, in a statement.
Company officials said they believe the biosimilar candidate has strong commercial potential in the North American marketplace. Indeed, Lucentis netted global sales of $2.1 billion in 2019.
COVID-19 has forced modifications in clinical trials to accommodate for patients’ inability to get to clinics. The danger of COVID-19 infections has also forced curtailment of some trial activities. However, Xbrane in April reported that it is on track toward approval of Xlucane ahead of the European expiration of Lucentis’ patent in 2022.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.